Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
University of Zaragoza
Centre Hospitalier Universitaire Vaudois
Tuberculosis Vaccine Initiative (TBVI)
European Union
Information provided by (Responsible Party):
Biofabri, S.L
ClinicalTrials.gov Identifier:
NCT02013245
First received: December 3, 2013
Last updated: December 11, 2013
Last verified: December 2013
  Purpose

The purpose of this study is to test the safety and immunogenicity of MTBVAC as a potential substitute for BCG vaccination.BCG vaccination has indeed demonstrated its major limitation in inducing protection against tuberculosis (TB). Novel vaccines are essential to fight against the current world epidemics in tuberculosis and resistance to anti-TB drugs.


Condition Intervention
Tuberculosis
Healthy
Biological: Biological MTBVAC and biological BCG (commercial)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Phase I Double Blind, Randomized, Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC in Comparison With BCG in Elispot TB(ESAT-6, CFP10, PPD)- and HIV- Negative Volunteers

Resource links provided by NLM:


Further study details as provided by Biofabri, S.L:

Primary Outcome Measures:
  • Safety and reactogenicity for all subjects. [ Time Frame: 7 months follow up ] [ Designated as safety issue: Yes ]

    Safety and reactogenicity for all subjects as determined by:

    • Occurrence of solicited symptoms during the 7-day follow-up period following vaccination and occurrence of unsolicited symptoms during the 210-day follow-up period following vaccination.
    • Occurrence of grade 3 vaccine related local and general symptoms during the 210-day follow-up period following vaccination and occurrence of serious adverse events throughout the entire study period.
    • Haematological and biochemical safety test levels prior and after vaccination


Secondary Outcome Measures:
  • Cell mediated immune response assessment [ Time Frame: 7 months follow up ] [ Designated as safety issue: No ]

Enrollment: 36
Study Start Date: January 2013
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Cohort 1
Biological: MTBVAC Biological: BCG (BCG Dose: 5 x 10e5 cfu/0.1ml)
Biological: Biological MTBVAC and biological BCG (commercial)
Cohort 2
Biological: MTBVAC Biological: BCG (BCG Dose: 5 x 10e5 cfu/0.1ml)
Biological: Biological MTBVAC and biological BCG (commercial)
Cohort 3
Biological: MTBVAC Biological: BCG (BCG Dose: 5 x 10e5 cfu/0.1ml)
Biological: Biological MTBVAC and biological BCG (commercial)

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Adults aged 18 to 45 years, ELISPOT Tb and HIV negative

Criteria

Inclusion Criteria:

  • Subjects who the Investigator believes that they can and will comply with the requirements of the protocol
  • Subjects who have no evidence of exposition to BCG as demonstrated by a ELISPOT PPD assay along with no history of BCG vaccination and no BCG scar
  • A male or female between, and including, 18 and 45 years of age at the time of the vaccination.
  • Written informed consent obtained from the subject prior to any study procedure.
  • If the subject is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception
  • Clinically acceptable laboratory values for blood tests.
  • Seronegative for human immunodeficiency virus 1 and -2 (HIV-1/2) antibodies, p24 antigen, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibodies.
  • No evidence of pulmonary pathology as confirmed by chest X-ray.
  • No history of extrapulmonary TB.
  • No history of previous contact with M. tuberculosis (latent tuberculosis) as demonstrated by a negative ELISPOT Tb (ESAT-6, CFP10) assay.

Exclusion Criteria:

  • History of allergic reactions (significant IgE-mediated events) or anaphylaxis to previous immunisations (any vaccine).
  • History of allergic disease or reactions
  • History of previous administration of experimental Mycobacterium tuberculosis vaccines.
  • Use of any investigational or non-registered product (drug or vaccine) in another experimental protocol other than the study vaccines within 30 days preceding the vaccination, or planned use during the study period.
  • Any chronic drug therapy to be continued during the study period.
  • Chronic administration of immunosuppressors or other immune-modifying drugs.
  • Administration of any immunoglobulins, any immunotherapy and/or any blood products within the three months preceding the vaccination, or planned administrations during the study period.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition (including HIV) based on medical history and physical examination.
  • Any condition or history of any acute or chronic illness or medication which, in the opinion of the Investigator, may interfere with the evaluation of the study objectives.
  • A family history of congenital or hereditary immunodeficiency.
  • A stay of more than 2 months in a highly endemic area (e.g. Eastern Europe (Romania, Bulgaria) and low-income countries) within 6 months prior to the screening visit or travel of more than 2 months foreseen in an area of high endemicity after the enrolment into the study.
  • History of any neurologic disorders or seizures.
  • History of chronic alcohol consumption and/or drug abuse.
  • Major congenital defects.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02013245

Locations
Switzerland
Centre Hospitalier Universitaire Vaudois
Lausanne, Canton of Vaud, Switzerland, 1011
Sponsors and Collaborators
Biofabri, S.L
University of Zaragoza
Centre Hospitalier Universitaire Vaudois
Tuberculosis Vaccine Initiative (TBVI)
European Union
Investigators
Principal Investigator: François Spertini, MD Centre Hospitalier Universitaire Vaudois
  More Information

Publications:

Responsible Party: Biofabri, S.L
ClinicalTrials.gov Identifier: NCT02013245     History of Changes
Other Study ID Numbers: MTBVAC-01
Study First Received: December 3, 2013
Last Updated: December 11, 2013
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Tuberculosis
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Mycobacterium Infections

ClinicalTrials.gov processed this record on October 22, 2014